Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  International Business Machines Corp.    IBM

Delayed Quote. Delayed  - 09/26 10:02:33 pm
153.98 USD   -0.65%
11:30a THE BUFFALO BIL : Corruption and pay-to-play, a symbol of everything..
08:28a INTERNATIONAL B : Bank of Tokyo-Mitsubishi UFJ, IBM pilot blockchain..
01:07a INTERNATIONAL B : IBM wants to expand in Ethiopia
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

International Business Machines Corp. : Memorial Sloan-Kettering Cancer Center, IBM to Collaborate in Applying Watson Technology to Help Oncologists

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/22/2012 | 03:35pm CEST

New York City - 22 Mar 2012: Memorial Sloan-Kettering Cancer Center (MSKCC) and IBM (NYSE: IBM) have agreed to collaborate on the development of a powerful tool built upon IBM Watson in order to provide medical professionals with improved access to current and comprehensive cancer data and practices. The resulting decision support tool will help doctors everywhere create individualized cancer diagnostic and treatment recommendations for their patients based on current evidence.

The initiative will combine the computational power of IBM Watson and its natural language processing ability with MSKCC's clinical knowledge, existing molecular and genomic data and vast repository of cancer case histories, in order to create an outcome and evidence-based decision support system. The goal is to give oncologists located anywhere the ability to obtain detailed diagnostic and treatment options based on updated research that will help them decide how best to care for an individual patient.

The IBM Watson system gained fame by beating human contestants on the television quiz show Jeopardy! It can interpret queries in natural language and uses statistical analysis, advanced analytics and a powerful array of processors to search millions of pages in seconds and deliver evidence-based statistically-ranked responses.

MSKCC's world-renowned oncologists will assist in developing IBM Watson to use a patient's medical information and synthesize a vast array of continuously updated and vetted treatment guidelines, published research and insights gleaned from the deep experience of MSKCC clinicians to provide an individualized recommendation to physicians. The tool will also provide users with a detailed record of the data and evidence used to reach the recommendations.

The need for such an advanced technology arises from the steadily increasing complexity of oncology treatment. Cancers are the second most common cause of death in the U.S., second only to heart disease, and the American Cancer Society projects that 1.6 million new cancer cases will be diagnosed in the U.S. this year* with outcomes varying widely across the country. Cancer is not one disease but some hundreds of sub-types, each with a different genetic fingerprint. Significant discoveries in molecular biology and genetics in the past two decades have delivered new insights into cancer biology and strategies for targeting specific molecular alterations in tumors, but these advances have also ratcheted up the complexity of diagnosing and treating each case. Oncologists and physicians who do not specialize in specific sub-types of cancer face a significant challenge in keeping up with the magnitude of rapidly changing information.

 "The combination of transformational technologies found in Watson with our cancer analytics and decision-making process has the potential to revolutionize the accessibility of information for the treatment of cancer in communities across the country and around the world," said MSKCC President and CEO Craig B. Thompson. "Consistent with our mission, the vision is to help better identify and personalize cancer therapies for each individual patient, no matter where that patient may be receiving care. We also expect tremendous new research opportunities to emerge from this collaboration."

"Memorial Sloan-Kettering's evidence-based clinical approach, scientific acumen, and vast database make it the ideal partner in this ambitious project," said Dr. Martin Kohn, chief medical scientist, IBM. "Cancer care is profoundly complex with continuous clinical and scientific advancements to consider. This field of clinical information, given its importance on both a human and economic level, is exactly the type of grand challenge IBM Watson can help address."

"This comprehensive, evidence-based approach will profoundly enhance cancer care by accelerating the dissemination of practice-changing research at an unprecedented pace," said Dr. Mark G. Kris, Chief, Thoracic Oncology Service at MSKCC and one of the clinicians leading the development effort. He noted that 85 percent of patients with cancer are not treated at specialized medical centers and it can take years for the latest developments in oncology to reach all practice settings.

Development work is already underway for the first applications, which include lung, breast and prostate cancers. The objective is to begin piloting the solutions to a select group of oncologists in late 2012, with wider distribution planned for late 2013. This collaboration complements an earlier announcement by IBM and WellPoint that the parties will focus on putting Watson to work on oncology solutions. 

About Memorial Sloan-Kettering Cancer Center

Memorial Sloan-Kettering Cancer Center is the world's oldest and largest private institution devoted to prevention, patient care, research, and education in cancer. Our scientists and clinicians generate innovative approaches to better understand, diagnose, and treat cancer. Memorial Sloan-Kettering specialists are leaders in biomedical research and in translating the latest research to advance the standard of cancer care worldwide. For more information, go to www.mskcc.org

*American Cancer Society, Cancer Facts and Figures 2012. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.

distributed by

This press release was issued by IBM - International Business Machines Corporation and was initially posted at http://www-03.ibm.com/press/us/en/pressrelease/37235.wss . It was distributed, unedited and unaltered, by noodls on 2012-03-22 15:27:46 PM. The issuer is solely responsible for the accuracy of the information contained therein.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INTERNATIONAL BUSINESS MAC
11:30a THE BUFFALO BILLION FRAUD AND BRIBER : Corruption and pay-to-play, a symbol of e..
08:28a INTERNATIONAL BUSINESS MACHINES : Bank of Tokyo-Mitsubishi UFJ, IBM pilot blockc..
01:07a INTERNATIONAL BUSINESS MACHINES : IBM wants to expand in Ethiopia
09/26 IBM : Provides Real-Time Payment Processing for Banks with new Financial Transac..
09/26 AVNET : to Launch MakerSource.io Directory at N.Y. World Maker Faire Will Team w..
09/26 INTERNATIONAL BUSINESS MACHINES : ABS claims IBM`s botched geoblocking failed th..
09/26 INTERNATIONAL BUSINESS MACHINES : CONTRACT AWARD - Notice of Intent to Sole Sour..
09/26 INTERNATIONAL BUSINESS MACHINES : Walkbase Launches IoT Platform For Retail on I..
09/26 INTERNATIONAL BUSINESS MACHINES : IBM announces next implementation of Apples Sw..
09/25 Imperva jumps on IBM, Cisco acquisition reports
More news
Sector news : IT Services & Consulting - NEC
09/26DJDisney Working With Adviser on Possible Twitter Bid -Bloomberg
09/26DJTWITTER : Is Eyed To Spur Growth -- WSJ
09/25DJTWITTER : Salesforce Weighs Twitter Bid to Spur Growth
09/24DJSalesforce Circles Twitter -- WSJ
09/23DJTwitter Shares Surge on Takeover Report--6th Update
More sector news : IT Services & Consulting - NEC
News from SeekingAlpha
09/26 Who Should Acquire Imperva?
09/26 SILICOM : Worth A Look
09/26 The Way It Is Now In IT Merger Land - Cisco, IBM, Salesforce And Google On Th..
09/23 Introduction To My DG Portfolio And Retirement Strategy
09/23 Google And Salesforce Target Twitter
Advertisement
Financials ($)
Sales 2016 79 588 M
EBIT 2016 14 813 M
Net income 2016 11 898 M
Debt 2016 34 138 M
Yield 2016 3,40%
P/E ratio 2016 12,56
P/E ratio 2017 12,03
EV / Sales 2016 2,28x
EV / Sales 2017 2,28x
Capitalization 147 181 M
More Financials
Chart INTERNATIONAL BUSINESS MAC
Duration : Period :
International Business Mac Technical Analysis Chart | IBM | US4592001014 | 4-Traders
Full-screen chart
Technical analysis trends INTERNATIONAL BUS...
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 25
Average target price 156 $
Spread / Average Target 1,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Virginia M. Rometty Chairman, President & Chief Executive Officer
James J. Kavanaugh Senior Vice President-Transformation & Operations
Martin J. Schroeter Chief Financial Officer & Senior Vice President
Jeff Smith Chief Information Officer
Sidney Taurel Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
INTERNATIONAL BUSINESS..11.89%147 181
TATA CONSULTANCY SERVI..-1.23%71 167
INFOSYS LTD-5.96%35 615
COGNIZANT TECHNOLOGY S..-9.78%32 866
NETEASE INC (ADR)33.09%31 709
VMWARE, INC.29.82%31 169
More Results